/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CELCUITY INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$99.8 0.0256(2.56%) CELC at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 97.93
Highest Today 101.48
Today’s Open 98.535
Prev. Close 97.5
52 Week High 103.06
52 Week Low 7.58
Day’s Range: Low 97.93 High 101.48
52-Week Range: Low 7.58 High 103.06
1 day return -
1 Week return -1.24
1 month return +36.75
3 month return +83.5
6 month return +730.42
1 year return +685.06
3 year return +1192.36
5 year return +783.28
10 year return -

Institutional Holdings

Baker Bros Advisors LP 12.85

Bvf Inc 8.17

Soleus Capital Management, L.P. 7.10

NEA Management Company, LLC 5.41

BlackRock Inc 4.88

Vanguard Group Inc 3.93

Perceptive Advisors LLC 3.85

Eventide Asset Management, LLC 3.27

Eventide Healthcare & Life Sciences I 3.27

Saturn V Capital Management LLC 2.79

Vanguard Total Stock Mkt Idx Inv 2.65

BRAIDWELL LP 2.08

Morgan Stanley - Brokerage Accounts 1.85

Ameriprise Financial Inc 1.81

Citadel Advisors Llc 1.78

iShares Russell 2000 ETF 1.67

Geode Capital Management, LLC 1.60

Vivo Capital, LLC 1.44

State Street Corp 1.38

CapTrust Financial Advisors 1.34

Columbia Small Cap Value Discovery Fund 1.23

Belfius Equities Cure C Cap 0.95

Artisan Partners Limited Partnership 0.95

Pfizer Inc 0.82

Vanguard Institutional Extnd Mkt Idx Tr 0.71

Fidelity Small Cap Index 0.68

Artisan International Small-Mid Investor 0.64

Artisan Non-U.S. Small-Mid Growth Comp 0.64

Candriam Luxembourg S.C.A. 0.62

iShares Russell 2000 Growth ETF 0.57

AB Small Cap Growth A 0.49

Candriam Eqs L Biotech C USD Cap 0.45

Fidelity Extended Market Index 0.36

Columbia Small Cap Value Discv A 0.32

Vanguard Russell 2000 ETF 0.32

Schwab US Small-Cap ETF™ 0.31

State St Russell Sm Cap® Indx SL Cl I 0.19

iShares Genomics Immnlgy & Hlthcr ETF 0.18

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.16

Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4511.45 M

PB Ratio 40.0116

PE Ratio 0.0

Enterprise Value 4545.24 M

Total Assets 245.12 M

Volume 735192

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-56511990 -56.5M, FY22:-41348989 -41.3M, FY21:-30564381 -30.6M, FY20:-9088704 -9.1M, FY19:-7020527 -7.0M

Quarterly Revenue Q3/2025:154000 0.2M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:77000 0.1M, Q2/2025:-40000 -0.0M, Q1/2025:-37000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-31115 -0.0M

Quarterly Net worth Q3/2025:-43804000 -43.8M, Q2/2025:-45268000 -45.3M, Q1/2025:-36997000 -37.0M, Q3/2024:-29791789 -29.8M, Q2/2024:-23721820 -23.7M

Fund house & investment objective

Company Information Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Organisation Biotechnology

Employees 87

Industry Biotechnology

CEO Mr. Brian F. Sullivan

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow